NeuroVision has acquired Durin Life Sciences, creating an integrated diagnostics and care platform focused on earlier detection, improved patient access, and longitudinal management of neurodegenerative disease. The combined company brings together blood‑based biomarker diagnostics, retinal imaging technology, and a national telehealth infrastructure designed to support patients, providers, and healthcare organizations across the United States. The unified platform will operate under the NeuroVision name and continue to be led by Steven Verdooner, the company’s CEO and co‑founder.
The acquisition pairs Durin’s blood‑based biomarker platform with NeuroVision’s retinal imaging capabilities and its BrainHealth.net patient engagement ecosystem. Together, the companies aim to accelerate the development and commercialization of diagnostic solutions for Alzheimer’s disease, Parkinson’s disease, ALS, and related neurological disorders. By combining advanced biomarker science with scalable clinical and data infrastructure, the company intends to support earlier intervention and more personalized care pathways.
Durin Life Sciences developed Duritect, a suite of rapid‑result blood‑based diagnostic tests designed to detect and monitor neurodegenerative disease, in some cases years before symptoms appear. NeuroVision contributes its telehealth‑enabled cognitive assessment tools, care navigation services, and longitudinal brain health programs, which are already used by patients and healthcare organizations nationwide. The combined capabilities are intended to create a more accessible, patient‑centered approach to brain health management.
The acquisition also brings new leadership alignment, with Ric Edelman, the majority owner of Durin, joining the board of the combined enterprise. NeuroVision emphasized that the integration of diagnostics, imaging, telehealth, and patient engagement will allow the company to support individuals and families throughout the entire care journey. The company plans to expand its partnerships with healthcare systems, academic institutions, and industry collaborators to advance innovation in neurological care.
KEY QUOTES:
“We’ve long believed that the future of neurodegenerative disease care begins with earlier and more accessible detection. Durin’s blood‑based biomarker platform represents an important advancement in that direction.”
Steven Verdooner, Chief Executive Officer of NeuroVision
“This is a milestone for Durin and for everyone who has been part of our journey, and we’re excited to be joining forces with NeuroVision.”
Ric Edelman, Majority Owner of Durin Life Sciences
